-
公开(公告)号：US07605126B2
公开(公告)日：2009-10-20
申请号：US11503502
申请日：2006-08-11
申请人： Deqiang Niu , Joel D. Moore , Dong Liu , Yonghua Gai , Zhigang Chen , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Joel D. Moore , Dong Liu , Yonghua Gai , Zhigang Chen , Yat Sun Or , Zhe Wang
CPC分类号： C07D487/04 , C07D403/14 , C07D409/14 , C07D417/14
摘要： The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了式I和II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20080039470A1
公开(公告)日：2008-02-14
申请号：US11503502
申请日：2006-08-11
申请人： Deqiang Niu , Joel D. Moore , Dong Liu , Yonghua Gai , Zhigang Chen , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Joel D. Moore , Dong Liu , Yonghua Gai , Zhigang Chen , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/40 , A61K31/498 , A61P31/14 , C07D207/00 , C07D241/36 , C07D245/02
CPC分类号： C07D487/04 , C07D403/14 , C07D409/14 , C07D417/14
摘要： The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了式I和II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US08962551B2
公开(公告)日：2015-02-24
申请号：US12327538
申请日：2008-12-03
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
CPC分类号： C07D487/04 , A61K38/212 , A61K38/215 , C07K5/06165 , C07K5/0812 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US08501681B2
公开(公告)日：2013-08-06
申请号：US11768712
申请日：2007-06-26
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
CPC分类号： C07D245/04 , A61K38/212 , A61K38/215 , C07D403/12 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
5.发明授权公开(公告)号：US08809264B2
公开(公告)日：2014-08-19
申请号：US11768723
申请日：2007-06-26
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00 , C07D245/04 , A61K38/21 , C07D403/12
CPC分类号： C07D245/04 , A61K38/212 , A61K38/215 , C07D403/12 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20090180981A1
公开(公告)日：2009-07-16
申请号：US12327538
申请日：2008-12-03
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
CPC分类号： C07D487/04 , A61K38/212 , A61K38/215 , C07K5/06165 , C07K5/0812 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译： 本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
7.发明申请公开(公告)号：US20090005387A1
公开(公告)日：2009-01-01
申请号：US12016599
申请日：2008-01-18
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/495 , A61K31/497 , A61P31/00
CPC分类号： A61K31/497 , A61K31/495 , A61K38/13 , A61K38/212 , A61K38/215 , C07D245/04 , C07D403/12 , C07D487/04 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20080008681A1
公开(公告)日：2008-01-10
申请号：US11768712
申请日：2007-06-26
申请人： Deqiang Niu , Dong Liu , Joel Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , A61K31/498 , A61P31/12 , C07D245/04
CPC分类号： C07D245/04 , A61K38/212 , A61K38/215 , C07D403/12 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
9.发明申请DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS 有权含有大分子化合物作为丙型肝炎病毒抑制剂公开(公告)号：US20090274657A1
公开(公告)日：2009-11-05
申请号：US12433191
申请日：2009-04-30
申请人： Yonghua Gai , Dong Liu , Joel D. Moore , Yat Sun Or , Zhe Wang
发明人： Yonghua Gai , Dong Liu , Joel D. Moore , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D241/36 , A61K31/4985 , A61K31/70 , A61P31/12
CPC分类号： C07D513/22 , C07D498/22 , C07D515/22
摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
10.发明授权Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors 有权含二氟甲基的大环化合物作为丙型肝炎病毒抑制剂公开(公告)号：US08211891B2
公开(公告)日：2012-07-03
申请号：US12433191
申请日：2009-04-30
申请人： Yonghua Gai , Dong Liu , Joel D. Moore , Yat Sun Or , Zhe Wang
发明人： Yonghua Gai , Dong Liu , Joel D. Moore , Yat Sun Or , Zhe Wang
IPC分类号： C07D225/00 , C07D295/00 , A61K31/495 , A61P31/22
CPC分类号： C07D513/22 , C07D498/22 , C07D515/22
摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.035 秒)
